Long-term management of thrombocytosis in essential thrombocythaemia

Birgegård, Gunnar
January 2009
Annals of Hematology;Jan2009, Vol. 88 Issue 1, p1
Academic Journal
Essential thrombocythaemia (ET) is an acquired myeloproliferative disorder with a prolonged clinical course and a near-normal life expectancy. Therapy is stratified according to risk of thrombohaemorrhagic events. In high-risk patients, platelet reduction is generally recommended. In intermediate-risk patients, therapy should be considered depending on the severity of associated risk factors, especially cardiovascular. In low-risk patients, a watch-and-wait approach is appropriate. Hydroxycarbamide is generally first-line therapy. Concerns for possible leukemogenicity make anagrelide or interferon-α possible choices in younger patients and those who are resistant or intolerant to hydroxycarbamide. Each pharmacotherapy is associated with specific long-term risks and benefits. The potential risk of major bleeding is the main drawback of aspirin. Hydroxycarbamide is an established, effective drug for ET, but it may increase the risk of transformation to acute myeloid leukaemia and may give mucocutaneous ulcers. Anagrelide is a licensed treatment that also reduces platelet counts and is generally well tolerated, with evidence that some common side effects diminish over time. Anagrelide can have cardiac effects due to inhibition of phosphodiesterase III and therefore requires cautious use in patients with cardiac insufficiency. There is no evidence of leukaemogenicity with anagrelide or interferon-α therapy. Interferon-α is the only treatment suitable for use during pregnancy, although it is not licensed in ET. While it is effective for platelet reduction, the use of interferon-α is restricted by psychiatric side effects. Our knowledge of the optimum pharmacotherapy for each patient with ET continues to evolve through research and clinical trials, particularly into the molecular basis of the disease.


Related Articles

  • Bone metabolism during interferon-alpha treatment of essential thrombocythemia. Kusec, Rajko; Kusec, Vesna; Gisslinger, Bettina; Woloszczuk, Wolfgang; Gisslinger, Heinz // Wiener Klinische Wochenschrift;2004, Vol. 116 Issue 1/2, p37 

    In-vitro studies have demonstrated that interferon (IFN) has an inhibitory effect on bone formation. Changes in bone metabolism were investigated in 19 patients treated for essential thrombocythemia with IFN-alpha. Serum biochemical parameters of bone remodeling [total alkaline phosphatase,...

  • Myeloproliferative disorders: complications, survival and causes of death. Brodmann, S.; Passweg, J. R.; Gratwohl, A.; Tichelli, A.; Skoda, R. C. // Annals of Hematology;Jun2000, Vol. 79 Issue 6, p312 

    This retrospective single-center study compared thromboembolic and hemorrhagic complications, survival and causes of death in a cohort of 102 consecutive patients with myeloproliferative disorders (MPD). We included 17 patients with essential thrombocythemia (ET), 59 with polycythemia vera (PV),...

  • Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Magnus Hultdin; Gunnel Sundström; Anders Wahlin; Berith Lundström; Jan Samuelsson; Gunnar Birgegård; Anna Engström-Laurent // Medical Oncology;Jan2007, Vol. 24 Issue 1, p63 

    Abstract  Anagrelide is a second-line option for reduction of thrombocythemia in patients with chronic myeloproliferative disorders (CMPDs). A multicenter, open, phase II study of anagrelide treatment in 60 patients during 2 yr was performed by the Swedish Myeloproliferative Disorder Study...

  • The Long-term Outlook for Essential Thrombocythemia. Campbell, Peter J.; Green, Anthony R. // Mayo Clinic Proceedings;Feb2006, Vol. 81 Issue 2, p157 

    The article discusses the importance of studies on long-term consequences of essential thrombocythemia (ET), a myeloproliferative disorders. Such studies could provide diagnostic work-up and management approaches, comprehensive and complete clinical follow-up, and standardized end point...

  • Familial essential thrombocythemia with spontaneous megakaryocyte colony formation and acquired JAK2 mutations. Higgs, J. R.; Sadek, I.; Neumann, P. E.; Ing, V. W.; Renault, N. K.; Berman, J. N.; Greer, W. L. // Leukemia (08876924);Aug2008, Vol. 22 Issue 8, p1551 

    Essential thrombocythemia (ET) is a chronic myeloproliferative disorder, characterized by increased proliferation of megakaryocytes and elevated platelet count that usually occurs sporadically. We report a family with seven affected individuals in three generations, including one individual with...

  • The Role of the MPL Receptor in Myeloproliferative Disorders. Kaushansky, Kenneth // Leukemia (08876924);Sep98 Supplement, Vol. 12, pS47 

    Thrombopoietin (TPO) is a primary regulator of megakaryopoiesis and thrombopoiesis, and has recently been identified as the ligand for the cytokine receptor MPL. Several lines of evidence suggest that dysregulation of MPL expression or TPO production are implicated in the pathogenesis of various...

  • Transitions Among the Myeloproliferative Disorders. Glasser, Robert M.; Walker, Richard I. // Annals of Internal Medicine;Aug69, Vol. 71 Issue 2, p285 

    Indicates that transitions among the three major disorders included in the myeloproliferative syndrome do not occur. Difficulty of proving the relationship between chronic myelogenous leukemia and myelofibrosis with myeloid metaplasia; Conclusions.

  • Nonfamilial, MPL S505N-Mutated Essential Thrombocythaemia. Morrell, Ruth; Langabeer, Stephen E.; Smyth, Liam; Perera, Meegahage; Crotty, Gerard // Case Reports in Hematology;2013, p1 

    Mutations of MPL are present in a significant proportion of patients with the myeloproliferative neoplasms (MPN), primary myelofibrosis (PMF), and essential thrombocythaemia (ET). The most frequent of these mutations, W515L and W515K, occur in exon 10 of MPL, which encodes the receptor for...

  • MUTAÅ¢IA JAK2V617F: CORELAÅ¢II CLINICE ÅŸI DE LABORATOR LA 104 PACIENÅ¢I CU TROMBOCITEMIE. Urian, Laura; Petrov, L.; Trifa, A.P.; Bojan, Anca // Acta Medica Transilvanica;jun2011, Vol. 16 Issue 2, p55 

    The myeloproliferative disorders or neoplasms (MPN) are heterogeneous diseases that occur at the level of a multipotent hematopoietic stem cell. They are characterized by incresed blood cell production and virtually normal cell maturation. Essential thrombocythemia (ET) is currently classified,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics